Ariel Hammerman

1.8k total citations · 3 hit papers
63 papers, 1.2k citations indexed

About

Ariel Hammerman is a scholar working on Economics and Econometrics, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Ariel Hammerman has authored 63 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Economics and Econometrics, 17 papers in Endocrinology, Diabetes and Metabolism and 12 papers in Surgery. Recurrent topics in Ariel Hammerman's work include Diabetes Treatment and Management (16 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Economic and Financial Impacts of Cancer (11 papers). Ariel Hammerman is often cited by papers focused on Diabetes Treatment and Management (16 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Economic and Financial Impacts of Cancer (11 papers). Ariel Hammerman collaborates with scholars based in Israel, United States and Canada. Ariel Hammerman's co-authors include Ronen Arbel, Ruslan Sergienko, Alon Peretz, Doron Netzer, Shlomit Yaron, Michael Friger, Erez Battat, Shmuel Klang, Sari Greenberg‐Dotan and Joseph Azuri and has published in prestigious journals such as New England Journal of Medicine, Circulation and Nature Medicine.

In The Last Decade

Ariel Hammerman

59 papers receiving 1.2k citations

Hit Papers

Nirmatrelvir Use and Severe Covid-19 Outcomes during the ... 2022 2026 2023 2024 2022 2023 2023 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
    2022 197 citations Ronen Arbel, Ruslan Sergienko et al. profile →
  2. Real-world effectiveness of a single dose of mpox vaccine in males
    2023 119 citations Ariel Hammerman, Ronen Arbel et al. profile →
  3. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study
    2023 86 citations Ronen Arbel, Ruslan Sergienko et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ariel Hammerman Israel 15 348 203 185 181 159 63 1.2k
Jeong-Gun Park United States 10 258 0.7× 142 0.7× 79 0.4× 85 0.5× 167 1.1× 13 882
Andrew J. Innes United Kingdom 21 169 0.5× 125 0.6× 135 0.7× 214 1.2× 35 0.2× 84 1.3k
Ruth Smith United Kingdom 16 532 1.5× 434 2.1× 134 0.7× 171 0.9× 37 0.2× 23 1.3k
Giorgio Lorenzo Colombo Italy 19 129 0.4× 388 1.9× 128 0.7× 55 0.3× 152 1.0× 75 1.1k
Lisa J. McQuay United States 15 336 1.0× 214 1.1× 60 0.3× 111 0.6× 49 0.3× 27 1.1k
Christine Hartman United States 15 219 0.6× 185 0.9× 109 0.6× 53 0.3× 19 0.1× 26 737
Mohamed Janabi Tanzania 14 170 0.5× 221 1.1× 55 0.3× 224 1.2× 20 0.1× 55 864
Weili He United States 16 546 1.6× 657 3.2× 185 1.0× 110 0.6× 167 1.1× 51 1.4k
Nadine Binder Germany 13 137 0.4× 190 0.9× 102 0.6× 132 0.7× 40 0.3× 31 982
Lesley S. Park United States 19 642 1.8× 600 3.0× 543 2.9× 64 0.4× 33 0.2× 36 1.7k

Countries citing papers authored by Ariel Hammerman

Since Specialization
Citations

This map shows the geographic impact of Ariel Hammerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ariel Hammerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ariel Hammerman more than expected).

Fields of papers citing papers by Ariel Hammerman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ariel Hammerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ariel Hammerman. The network helps show where Ariel Hammerman may publish in the future.

Co-authorship network of co-authors of Ariel Hammerman

This figure shows the co-authorship network connecting the top 25 collaborators of Ariel Hammerman. A scholar is included among the top collaborators of Ariel Hammerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ariel Hammerman. Ariel Hammerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Azran, Carmil, et al.. (2024). Can Consultation by a Clinical Pharmacist Prevent Morbidity and Mortality in Patients Undergoing Bariatric Surgery?. Journal of Clinical Medicine. 13(2). 310–310. 3 indexed citations
2.
3.
Azuri, Joseph, et al.. (2023). Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis. Obesity. 31(6). 1510–1513. 17 indexed citations
4.
Tsaban, Gal, Adam Solomon, Jean Marc Weinstein, et al.. (2023). Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis. American Journal of Cardiovascular Drugs. 23(3). 323–328. 3 indexed citations
5.
Tsaban, Gal, Adam Solomon, Abed N. Azab, et al.. (2023). Dapagliflozin versus empagliflozin in patients with chronic kidney disease. Frontiers in Pharmacology. 14. 1227199–1227199. 6 indexed citations
6.
Azuri, Joseph, et al.. (2022). Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. Diabetes Obesity and Metabolism. 25(4). 961–964. 27 indexed citations
7.
Hammerman, Ariel, et al.. (2022). Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6. Postgraduate Medicine. 134(7). 654–658. 1 indexed citations
8.
Hammerman, Ariel, et al.. (2022). Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus. The American Journal of Cardiology. 170. 128–131. 2 indexed citations
9.
10.
Arbel, Ronen, et al.. (2021). Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis. The American Journal of Medicine. 134(7). e415–e419. 8 indexed citations
11.
12.
Arbel, Ronen, et al.. (2021). Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. The American Journal of Cardiology. 150. 65–68. 4 indexed citations
13.
Hammerman, Ariel, et al.. (2021). Dapagliflozin Versus Sacubitril–Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus. American Journal of Cardiovascular Drugs. 22(3). 325–331. 2 indexed citations
14.
Arbel, Ronen, Ariel Hammerman, & Joseph Azuri. (2019). Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. The American Journal of Cardiology. 123(8). 1273–1276. 10 indexed citations
15.
Arbel, Ronen, Ruslan Sergienko, Ariel Hammerman, et al.. (2019). Direct oral anticoagulation and mortality in moderate to high-risk atrial fibrillation. Heart. 105(19). 1487–1492. 4 indexed citations
16.
Greenberg, Dan, et al.. (2013). Are Israeli Adults Willing to Pay Higher Health Taxes for a Wider Coverage of Life-Extending Medications?. Value in Health. 16(7). A338–A338. 1 indexed citations
17.
18.
Hammerman, Ariel, Paula Feder‐Bubis, & Dan Greenberg. (2012). Financial Risk-Sharing in Updating the National List of Health Services in Israel: Stakeholders' Perceived Interests. Value in Health. 15(5). 737–742. 8 indexed citations
19.
20.
Hammerman, Ariel, et al.. (2000). [Israel hospital pharmaceutical services: a national survey].. PubMed. 138(10). 828–31, 911, 910. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeong-Gun Park Breakdown of academic impact, for papers by Andrew J. Innes Breakdown of academic impact, for papers by Ruth Smith Breakdown of academic impact, for papers by Giorgio Lorenzo Colombo Breakdown of academic impact, for papers by Lisa J. McQuay Breakdown of academic impact, for papers by Christine Hartman Breakdown of academic impact, for papers by Mohamed Janabi Breakdown of academic impact, for papers by Weili He Breakdown of academic impact, for papers by Nadine Binder Breakdown of academic impact, for papers by Lesley S. Park
Rankless by CCL
2026